Novel MRE Technique to Assess a Risk Factor for Liver Cancer

Sponsor

Natalie Torok (Other)

Overall Status

Recruiting

CT.gov ID

NCT05165446

Collaborator

(none)

Enrollment

Location

11.1

Anticipated Duration (Months)

3.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this proposal is to investigate a novel imaging method to identify patients with non-alcoholic steatohepatitis (NASH) who are at risk for hepatocellular carcinoma (HCC).

Condition or Disease	Intervention/Treatment	Phase
NASH - Nonalcoholic Steatohepatitis

Detailed Description

NASH is the most common cause of chronic liver disease, and it is estimated that 40-50% of patients with obesity and T2DM have NASH. NASH can lead to HCC with the risk increasing 2-3 fold in patient with poor glycemic control. Unless caught early, HCC has a poor prognosis with no effective therapies. A unique feature of HCC in NASH is that it often arises at a pre-cirrhotic stage, and the prognosis is often dismal. There are no current surveillance strategies for these pre-cirrhotic patients. Based on our animal models and pilot patient studies, we developed a novel paradigm that linked liver matrix changes to a more aggressive HCC phenotype. Our goal is to develop an imaging-based surveillance tool that will identify early matrix changes that may predispose to HCC.

Study Design

Study Type:

Observational

Anticipated Enrollment :

35 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Novel MRE Technique to Assess Tissue Viscoelasticity as a Risk Factor for Liver Cancer

Actual Study Start Date :

Jan 27, 2022

Anticipated Primary Completion Date :

Jan 1, 2023

Anticipated Study Completion Date :

Jan 1, 2023

Outcome Measures

Primary Outcome Measures

Novel MRE technique to assess tissue viscoelasticity as a risk factor for liver cancer [For individual patients: duration of the study 8 weeks (including lab, scheduling the MR and 4w post MR period).]
Safety:MRE evaluation of the liver for stiffness is a standard of care test. We do not expect issues as this is a non-invasive technique. Our MR may require a longer session compared to the traditional MRE (40 minutes of scan time for multifrequency MRE, as compared to 25 minutes for conventional MRE). However, all issues, patient symptoms will be recorded. Technical Feasibility: The MRE algorithm we will use has previously been shown to produce data from a different scanner platform, across all frequencies. Feasibility of multifrequency MRE will be assessed by descriptive summary of technical success and image quality for each of the individual reconstructed MRE datasets (stiffness, elasticity, and viscosity). Mean and standard deviation for the MRE outcome variables viscosity elasticity and stiffness will be presented and tested for the difference in means between the 2 groups by way of ANOVA, and if a difference is found, followed by Tukey's test.

Secondary Outcome Measures

Studies on liver injury and glycemic control. [For individual patients: duration of the study 8 weeks]
assess correlation to liver injury (AST, ALT) assess correlation to glycemic control HbA1c

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 99 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Male or non-pregnant/non-lactating women ≥ 18 years of age
Diagnosis of NASH
Diagnosis of pre-cirrhotic fibrosis (F1-F3), diagnosed as per standard of care (history, exam, laboratory tests, Fibroscan, within 6 months of enrollment)
Na-MELD < 9: The Na-MELD (sodium-Model for End Stage Liver Disease) score is routinely used to assess liver synthetic function and life expectancy. Patients with Na-MELD<9 have less than 1.9% 3 months liver-related mortality risk, and their liver synthetic function is normal.
Groups both with and without T2DM will be enrolled.
Women of childbearing potential must agree to at least two methods of contraception.
Will not participate in any other clinical trial for the duration of the study
Will not consume alcohol for the duration of the study
If on vitamin E, pioglitazone or any anti diabetic treatment prior to the study, will have been on stable therapies for 6 months prior to enrolment.
Able to undergo 3 Tesla MRI and complete MRI screening form
Ability to understand and the willingness to sign a written informed consent document.
ECOG or Karnofsky Performance Status will be not be employed

Exclusion Criteria:

Presence of any other form of liver disease, including viral hepatitis, autoimmune hepatitis, alcoholic liver disease, genetic causes of chronic liver disease, cardiogenic liver disease, and HIV positivity (can cause liver fibrosis).
ALT>300 U/l
Total serum bilirubin ≥ to 1.3 mg/dL (Gilbert's Syndrome patients are excepted)
International Normalized Ratio (INR) ≥ 1.3
MELD>9
Serum creatinine >2.0mg/dl
Known alcohol abuse or alcohol use disorder (AUDIT profile and/or pos. urine ethylglucuronide):